Zinnia Wealth Advisory LLC Invests $548,000 in Catalyst Pharmaceuticals, Inc. $CPRX

Zinnia Wealth Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,468 shares of the biopharmaceutical company’s stock, valued at approximately $548,000.

Several other large investors have also recently modified their holdings of CPRX. Rothschild Investment LLC boosted its stake in Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,520 shares in the last quarter. Advisory Services Network LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $39,000. Quarry LP purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $40,000. Clearstead Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,167 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $31.36 on Monday. The firm’s 50-day moving average price is $29.16 and its 200-day moving average price is $25.65. The company has a market cap of $3.84 billion, a PE ratio of 18.02, a PEG ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $31.50 in a research note on Thursday, May 28th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).